Candida species, belonging to commensal microbial communities in humans, cause
opportunistic infections in individuals with impaired immunity. Pathogens encountered in …

Patients with suppressed immunity are at the highest risk for hospital-acquired infections.
Among these, invasive candidiasis is the most prevalent systemic fungal nosocomial …

It is important to realize that guidelines cannot always account for individual variation among
patients. They are not intended to supplant physician judgment with respect to particular …

The European Conference on Infections in Leukemia (ECIL) provides recommendations for
diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various …

This analysis describes the epidemiology and outcomes of invasive candidiasis caused by
non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy …

Human fungal pathogens are attributable to a significant economic burden and mortality
worldwide. Antifungal treatments, although limited in number, play a pivotal role in …

Paediatric patients with cancer and those undergoing allogeneic haematopoietic cell
transplantation have an increased susceptibility to invasive fungal diseases. In addition to …

Candidemia and invasive candidiasis are the most common healthcare-associated invasive
fungal infections, with a crude mortality rate of 25–50%. Candida albicans remains the most …

The significant increase in the use of antifungal agents, both for the treatment of candidiasis
and invasive aspergillosis and as azole fungicides in agricultural crop protection has …

Candida parapsilosis is becoming a predominant non-albicans cause of invasive
candidiasis (IC). Echinocandins are the preferred choice for IC treatment and prophylaxis …